Back to Search
Start Over
Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum
- Source :
- European Journal of Pharmacology, 412(2), 127-138. ELSEVIER SCIENCE BV, European Journal of Pharmacology, 412(2), 127-138. Elsevier
- Publication Year :
- 2001
-
Abstract
- Dose-effect curves were established for the effects of the antipsychotic drugs haloperidol, clozapine, olanzapine, risperidone and ziprasidone on extracellular levels of dopamine and noradrenaline in the medial prefrontal cortex, and of dopamine in the striatum. Haloperidol was more effective in stimulating the release of dopamine in the striatum, whereas clozapine was much more effective in the medial prefrontal cortex. The efficacy of risperidone, olanzapine and ziprasidone did not differ for the two brain areas. The benzamides sulpiride and raclopride increased dopamine release in the striatum but did not affect the release of dopamine and noradrenaline in the medial prefrontal cortex. In the presence of dopamine/noradrenaline reuptake inhibitors, the benzamides strongly increased the release of dopamine-but not of noradrenaline-in the medial prefrontal cortex. The 5-HT2 receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (MDL100,907) (800 nmol/kg) and the dopamine D-2 receptor antagonist raclopride (2 mu mol/kg) displayed a clear synergism in increasing the release of dopamine in the medial prefrontal cortex. No such synergism was seen in the case of noradrenaline. Go-administration of the 5-HT2 receptor agonist (+)-2,5-dimethoxy-4-iodoamphetamine HCl (DOI) (850 nmol/kg) with clozapine (10 mu mol/kg) or haloperidol(800 nmol/kg) blocked the increase in dopamine as well as noradrenaline in the medial prefrontal cortex. It is concluded that typical and non-benzamide atypical antipsychotics increase extracellular dopamine in the medial prefrontal cortex via a synergistic interaction by blocking 5-HT2 as well as dopamine D-2 receptors. The increase in extracellular noradrenaline in the medial prefrontal cortex that was observed after administration of antipsychotics is explained by inhibition of 5-HT2 receptors and not dopamine D-2 receptors. Finally, the significance of the classification of antipsychotic drugs based on their selective action on the release of dopamine and noradrenaline in the medial prefrontal cortex is discussed. In particular, the position of the benzamides is discussed. (C) 2001 Elsevier Science B.V. All rights reserved.
- Subjects :
- Male
AMISULPRIDE
INCREASES
Dopamine
striatum
NUCLEUS-ACCUMBENS
Pharmacology
Nucleus accumbens
antipsychotic drug
NEGATIVE SYMPTOMS
RAT-BRAIN
Norepinephrine
chemistry.chemical_compound
Dopamine receptor D1
RECEPTOR ANTAGONIST
Dopamine receptor D2
medicine
RISPERIDONE
Animals
Rats, Wistar
Prefrontal cortex
Neurotransmitter
IN-VIVO
Raclopride
prefrontal cortex
Dose-Response Relationship, Drug
Chemistry
FRONTAL-CORTEX
Corpus Striatum
Rats
EXTRACELLULAR DOPAMINE
Receptors, Serotonin
Haloperidol
Sulpiride
Antipsychotic Agents
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 00142999
- Database :
- OpenAIRE
- Journal :
- European Journal of Pharmacology, 412(2), 127-138. ELSEVIER SCIENCE BV, European Journal of Pharmacology, 412(2), 127-138. Elsevier
- Accession number :
- edsair.doi.dedup.....7822f754eb70da9a9448ca2af7639708